Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

被引：3

作者：

Karapetyan, Lilit ^{[1
,2
]}

Luke, Jason J. ^{[3
,4
,5
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Univ S Florida, Dept Oncol Sci, Tampa, FL USA

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[5] 5150 Ctr Ave,Room 1 27C, Pittsburgh, PA 15232 USA

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 05期

关键词：

CELL; RELATLIMAB; NIVOLUMAB;

D O I：

10.1158/1078-0432.CCR-22-3312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti-PD-(L)1 in the IFNy associated T-cell-inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve immune checkpoint blockade. Soluble LAG-3 is an intriguing biomarker for LAG-3 drug activity.

引用

页码：835 / 837

页数：3

共 50 条

[41] LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
Sordo-Bahamonde, Christian
Lorenzo-Herrero, Seila
Gonzalez-Rodriguez, Ana P.
Payer, Angel R.
Gonzalez-Garcia, Esther
Lopez-Soto, Alejandro
Gonzalez, Segundo
CANCERS, 2021, 13 (09)
[42] LAG-3 and PD-1 synergize on CD8+T cells to drive T cell exhaustion and hinder autocrine IFN-y-dependent anti-tumor immunity
Andrews, Lawrence P.
Butler, Samuel C.
Cui, Jian
Cillo, Anthony R.
Cardello, Carly
Liu, Chang
Brunazzi, Erin A.
Baessler, Andrew
Xie, Bingxian
Kunning, Sheryl R.
Ngiow, Shin Foong
Manne, Sasikanth
Huang, Yinghui Jane
Sharpe, Arlene H.
Delgoffe, Greg M.
Wherry, E. John
Kirkwood, John M.
Bruno, Tulia C.
Workman, Creg J.
Vignali, Dario A. A.
CELL, 2024, 187 (16) : 4355 - 4372.e22
[43] Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells
Annunziato, F
Manetti, R
Cosmi, L
Galli, G
Heusser, CH
Romagnani, S
Maggi, E
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) : 2239 - 2244
[44] Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+T cells to promote antitumor immunity
Cillo, Anthony R.
Cardello, Carly
Shan, Feng
Karapetyan, Lilit
Kunning, Sheryl
Sander, Cindy
Rush, Elizabeth
Karunamurthy, Arivarasan
Massa, Ryan C.
Rohatgi, Anjali
Workman, Creg J.
Kirkwood, John M.
Bruno, Tullia C.
Vignali, Dario A. A.
CELL, 2024, 187 (16) : 4373 - 4388.e15
[45] Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Hamid, Omid
Lewis, Karl D.
Weise, Amy
McKean, Meredith
Papadopoulos, Kyriakos P.
Crown, John
Kim, Tae Min
Lee, Dae Ho
Thomas, Sajeve S.
Mehnert, Janice
Kaczmar, John
Lakhani, Nehal J.
Kim, Kevin B.
Middleton, Mark R.
Rabinowits, Guilherme
Spira, Alexander I.
Yushak, Melinda
Mehmi, Inderjit
Fang, Fang
Chen, Shuquan
Mani, Jayakumar
Jankovic, Vladimir
Wang, Fang
Fiaschi, Nathalie
Brennan, Laura
Paccaly, Anne
Masinde, Sheila
Salvati, Mark
Fury, Matthew G.
Kroog, Glenn
Lowy, Israel
Gullo, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24) : 2928 - 2938
[46] Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Datar, Ila
Sanmamed, Miguel F.
Wang, Jun
Henick, Brian S.
Choi, Jungmin
Badri, Ti
Dong, Weilai
Mani, Nikita
Toki, Maria
Mejias, Luis D.
Lozano, Maria D.
Luis Perez-Gracia, Jose
Velcheti, Vamsidhar
Hellmann, MatthewD.
Gainor, Justin F.
McEachern, Kristen
Jenkins, David
Syrigos, Konstantinos
Politi, Katerina
Gettinger, Scott
Rimm, David L.
Herbst, Roy S.
Melero, Ignacio
Chen, Lieping
Schalper, Kurt A.
CLINICAL CANCER RESEARCH, 2019, 25 (15) : 4663 - 4673
[47] TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells
Cianciotti, Beatrice Claudia
Magnani, Zulma Irene
Ugolini, Alessia
Camisa, Barbara
Merelli, Ivan
Vavassori, Valentina
Potenza, Alessia
Imparato, Antonio
Manfredi, Francesco
Abbati, Danilo
Perani, Laura
Spinelli, Antonello
Shifrut, Eric
Ciceri, Fabio
Vago, Luca
Di Micco, Raffaella
Naldini, Luigi
Genovese, Pietro
Ruggiero, Eliana
Bonini, Chiara
FRONTIERS IN IMMUNOLOGY, 2024, 15
[48] Characterization of 405B8H3(D-E), a newly engineered high affinity chimeric LAG-3 antibody with potent antitumor activity
Lan, Xiaoxuan
Yang, Teddy Tat Chi
Wang, Yinghui
Qu, Baoyuan
Rong, Shaofeng
Song, Ningning
FEBS OPEN BIO, 2023, 13 (07): : 1253 - 1265
[49] Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade
Principe, Nicola
Phung, Amber-Lee
Stevens, Kofi L. P.
Elaskalani, Omar
Wylie, Ben
Tilsed, Caitlin M.
Sheikh, Fezaan
Morales, M. Lizeth Orozco
Kidman, Joel
Marcq, Elly
Fisher, Scott A.
Nowak, Anna K.
Mcdonnell, Alison M.
Lesterhuis, W. Joost
Chee, Jonathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
[50] Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
Jung, Eun Hee
Jang, Hee Ryeong
Kim, Se Hyun
Suh, Koung Jin
Kim, Yu Jung
Lee, Ju-Hyun
Chung, Jin-Haeng
Kim, Miso
Keam, Bhumsuk
Kim, Tae Min
Kim, Dong-Wan
Heo, Dae Seog
Lee, Jong Seok
THORACIC CANCER, 2021, 12 (05) : 619 - 630

← 1 2 3 4 5 →